Merck to buy VC-backed Tilos Therapeutics

Merck has agreed to acquire Tilos Therapeutics, a biopharmaceutical company, for a consideration of up to $773 million. Tilos is backed by Boehringer Ingelheim Venture Fund, Partners Innovation Fund and ShangPharma Innovation Fund.

DealsNorth AmericaUSHealthcareBriefs